Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan L Parker

Showing results (1-10 of 83) with videos related to

Pageof 9
Sort By:
Cancers|August 26, 2023
Oncolytic Viruses and Immune Checkpoint Inhibitors: The "Hot" New Power CoupleCharlotte Lovatt, Alan L Parker
Journal for Immunotherapy of Cancer|May 13, 2025
GP73: the key to unlocking immunotherapies efficacy in solid tumors?Rebecca J Bayliss, Alan L Parker
Oncotarget|November 28, 2018
Precision virotherapies: Coming soonHanni Uusi-Kerttula, Alan L Parker
Clinical Medicine (London, England)|March 11, 2022
The aetiopathogenesis of vaccine-induced immune thrombotic thrombocytopeniaCheng-Hock Toh, Guozheng Wang, Alan L Parker
Journal of the American Chemical Society|January 5, 2002
Laterally stabilized complexes of DNA with linear reducible polycations: strategy for triggered intracellular activation of DNA delivery vectorsDavid Oupický, Alan L Parker, Leonard W Seymour
ACS Synthetic Biology|September 9, 2022
Pseudotyping Bacteriophage P2 Tail Fibers to Extend the Host Range for Biomedical ApplicationsTabitha G Cunliffe, Alan L Parker, Alfonso Jaramillo
Viruses|June 27, 2024
The Immune System-A Double-Edged Sword for Adenovirus-Based TherapiesRebecca Wallace, Carly M Bliss, Alan L Parker
Current Opinion in Molecular Therapeutics|October 3, 2008
Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applicationsAlan L Parker, Stuart A Nicklin, Andrew H Baker
Cancers|November 14, 2020
Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision VirotherapiesTabitha G Cunliffe, Emily A Bates, Alan L Parker
Human Gene Therapy|September 30, 2022
Engineering Cancer Selective Virotherapies: Are the Pieces of the Puzzle Falling into Place?Emma A Swift, Steven M Pollard, Alan L Parker
Pageof 9

Showing results (1-10 of 83) with videos related to

Sort By:
Pageof 9
Cancers|August 26, 2023
Oncolytic Viruses and Immune Checkpoint Inhibitors: The "Hot" New Power CoupleCharlotte Lovatt, Alan L Parker
Journal for Immunotherapy of Cancer|May 13, 2025
GP73: the key to unlocking immunotherapies efficacy in solid tumors?Rebecca J Bayliss, Alan L Parker
Oncotarget|November 28, 2018
Precision virotherapies: Coming soonHanni Uusi-Kerttula, Alan L Parker
Clinical Medicine (London, England)|March 11, 2022
The aetiopathogenesis of vaccine-induced immune thrombotic thrombocytopeniaCheng-Hock Toh, Guozheng Wang, Alan L Parker
Journal of the American Chemical Society|January 5, 2002
Laterally stabilized complexes of DNA with linear reducible polycations: strategy for triggered intracellular activation of DNA delivery vectorsDavid Oupický, Alan L Parker, Leonard W Seymour
ACS Synthetic Biology|September 9, 2022
Pseudotyping Bacteriophage P2 Tail Fibers to Extend the Host Range for Biomedical ApplicationsTabitha G Cunliffe, Alan L Parker, Alfonso Jaramillo
Viruses|June 27, 2024
The Immune System-A Double-Edged Sword for Adenovirus-Based TherapiesRebecca Wallace, Carly M Bliss, Alan L Parker
Current Opinion in Molecular Therapeutics|October 3, 2008
Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applicationsAlan L Parker, Stuart A Nicklin, Andrew H Baker
Cancers|November 14, 2020
Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision VirotherapiesTabitha G Cunliffe, Emily A Bates, Alan L Parker
Human Gene Therapy|September 30, 2022
Engineering Cancer Selective Virotherapies: Are the Pieces of the Puzzle Falling into Place?Emma A Swift, Steven M Pollard, Alan L Parker
Pageof 9